Literature DB >> 16816494

Antibiotics for treatment of resistant gram-positive coccal infections.

Hossam Al-Tatari1, Nahed Abdel-Haq, Pimpanada Chearskul, Basim Asmar.   

Abstract

Vancomycin is considered the workhorse for the treatment of most drug-resistant gram-positive bacterial infections. However, concerns have been raised regarding the increasing rates of vancomycin-resistant enterococci and the clinical shortcomings of vancomycin in the treatment of invasive Staphylococcus aureus infections. Resources have been committed to the development of antimicrobial agents with activity against these organisms. This review will focus on the newer antibacterial agents that have been developed for the treatment of resistant gram-positive pathogens. Included in this review are the agents: quinupristin-dalfopristin, linezolid, daptomycin, telithromycin, and tigecycline.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16816494     DOI： 10.1007/BF02825827

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN： 0019-5456            Impact factor:   5.319


  90 in total

1.  Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene.

Authors:  Soju Chang; Dawn M Sievert; Jeffrey C Hageman; Matthew L Boulton; Fred C Tenover; Frances Pouch Downes; Sandip Shah; James T Rudrik; Guy R Pupp; William J Brown; Denise Cardo; Scott K Fridkin
Journal:  N Engl J Med       Date:  2003-04-03       Impact factor: 91.245

2.  In vitro activities of tigecycline (GAR-936) and 12 other antimicrobial agents against 90 Eikenella corrodens clinical isolates.

Authors:  Emilia Cercenado; Sonia Cercenado; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

3.  Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates.

Authors:  D Milatovic; F-J Schmitz; J Verhoef; A C Fluit
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

4.  Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects.

Authors:  Gopal Muralidharan; Marlynne Micalizzi; John Speth; Donald Raible; Steven Troy
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

5.  Relative potency of telithromycin, azithromycin and erythromycin against recent clinical isolates of gram-positive cocci.

Authors:  A L Barry; P C Fuchs; S D Brown
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2001-07       Impact factor: 3.267

6.  In vitro pharmacodynamic studies of activities of ketolides HMR 3647 (Telithromycin) and HMR 3004 against extracellular or intracellular Helicobacter pylori.

Authors:  I Gustafsson; L Engstrand; O Cars
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

7.  Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study.

Authors:  E Rubinstein; S Cammarata; T Oliphant; R Wunderink
Journal:  Clin Infect Dis       Date:  2001-01-26       Impact factor: 9.079

8.  Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.

Authors:  T L Smith; M L Pearson; K R Wilcox; C Cruz; M V Lancaster; B Robinson-Dunn; F C Tenover; M J Zervos; J D Band; E White; W R Jarvis
Journal:  N Engl J Med       Date:  1999-02-18       Impact factor: 91.245

9.  Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001.

Authors:  Ian A Critchley; Deborah C Draghi; Daniel F Sahm; Clyde Thornsberry; Mark E Jones; James A Karlowsky
Journal:  J Antimicrob Chemother       Date:  2003-03       Impact factor: 5.790

Review 10.  Oxazolidinones: a review.

Authors:  D I Diekema; R N Jones
Journal:  Drugs       Date:  2000-01       Impact factor: 11.431
View more
  3 in total

1.  Heat stable antimicrobial activity of Burkholderia gladioli OR1 against clinical drug resistant isolates.

Authors:  Pratibha Bharti; Vivek Anand; Jagdish Chander; Inder Pal Singh; Tej Vir Singh; Rupinder Tewari
Journal:  Indian J Med Res       Date:  2012-05       Impact factor: 2.375

2.  Novel Peptides Targeting the β-Clamp Rapidly Kill Planktonic and Biofilm Staphylococcus epidermidis Both in vitro and in vivo.

Authors:  Synnøve Brandt Raeder; Erik Thorvaldsen Sandbakken; Anala Nepal; Kirsti Løseth; Kåre Bergh; Eivind Witsø; Marit Otterlei
Journal:  Front Microbiol       Date:  2021-03-17       Impact factor: 5.640

3.  Antimicrobial and Microbiological Characteristics of Critically Ill Patients with Complicated Intra-Abdominal Infection: Observational Data from Beth Israel Deaconess Medical Center.

Authors:  Yingmu Tong; Qinglin Li; Sinan Liu; Tong Liu; Kai Qu; Chang Liu; Jingyao Zhang
Journal:  Int J Gen Med       Date:  2022-02-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.